Cerebrolysin, Semax, Selank, Dihexa, and Pinealon: A Clinical Guide to Neurotropic Peptides

What Is Cerebrolysin and How Does It Work?

Cerebrolysin is a porcine brain-derived peptide mixture containing low-molecular-weight peptides and free amino acids that mimic the activity of endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). It crosses the blood-brain barrier and acts on multiple targets simultaneously: it upregulates BDNF gene expression, suppresses amyloid precursor protein cleavage by beta-secretase, inhibits caspase-3-mediated apoptosis, and reduces tau hyperphosphorylation [1].

The pharmacology is genuinely multi-target. A single 10 mL intravenous dose produces measurable changes in cerebrospinal fluid neurotrophic factor concentrations within 48 hours [2]. This is different from synthetic single-molecule drugs, which usually hit one receptor or enzyme. The mixture also contains roughly 25% free amino acids that serve as direct metabolic substrate for neurons under ischemic stress.

Cerebrolysin is approved and widely prescribed in Austria, Germany, Russia, China, and several post-Soviet states for acute ischemic stroke and Alzheimer's disease. In the United States it is not FDA-approved and is available only through compounding channels or international sourcing, both of which carry regulatory and quality-control risks.

The standard clinical cycle runs 10 mL to 30 mL IV once daily for 10 to 20 consecutive days [3]. Some Eastern European protocols extend to 30 days. Repeat cycles are often spaced 3 to 6 months apart, though no U.S. guideline specifies this interval.

What Does the Clinical Trial Evidence Show for Cerebrolysin?

Evidence is strongest in acute ischemic stroke and Alzheimer's disease, with meaningful randomized controlled trial data from both areas.

Ischemic stroke. The CASTA trial (N=1,070) was a Phase III, placebo-controlled RCT testing cerebrolysin 30 mL IV daily for 10 days started within 12 hours of stroke onset. The primary endpoint (modified Rankin Scale at 90 days) did not reach statistical significance for the full cohort [4]. However, a pre-specified subgroup analysis of moderate-to-severe strokes (NIHSS 12 to 22) showed a statistically significant 8.3-percentage-point improvement in favorable outcome (modified Rankin Scale 0 to 2) with cerebrolysin versus placebo (P<0.05) [4]. A 2020 Cochrane review of five cerebrolysin stroke trials (N=1,501 total) concluded that cerebrolysin "probably reduces the proportion of patients with poor outcomes" but called for larger confirmatory trials before routine clinical adoption [5].

Alzheimer's disease. A randomized trial by Gauthier et al. (N=279) testing cerebrolysin 30 mL IV three times weekly for 4 weeks followed by once weekly maintenance found statistically significant improvement on the ADAS-Cog at 12 weeks versus placebo (mean difference 3.2 points, P<0.01) [6]. A meta-analysis published in the Journal of Neural Transmission pooling six Alzheimer RCTs (N=662) found consistent short-term cognitive benefit, with effect sizes on the ADAS-Cog ranging from 2.1 to 4.4 points [7].

These numbers are clinically modest. For context, the FDA's threshold for Alzheimer's drug approval historically considers a 3-to-4 ADAS-Cog point difference meaningful over 6 months.

Semax: Mechanisms and Trial Data

Semax (MEHFPGP) is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) fragment 4-10. It does not bind the melanocortin receptors responsible for cortisol release, so it carries no endocrine steroid risk at standard doses [8]. Its primary actions are upregulation of BDNF and NGF within the rat hippocampus within 3 to 24 hours after a single intranasal dose, and modulation of serotonin, dopamine, and acetylcholine pathways [9].

Semax is approved in Russia for ischemic stroke, transient ischemic attack, and cognitive impairment. At least two Russian multicenter RCTs (total N~600) demonstrated significant improvement in NIHSS scores at 10 days when semax 0.1% nasal spray was given 600 mcg twice daily starting within 6 hours of stroke onset [10]. An open-label trial in children with attention-deficit disorder (N=32) found statistically significant improvements on the Conners rating scale at 30 days (P<0.05), though the small size limits conclusions [11].

In practice, U.S. physicians using semax off-label typically start at 300 mcg intranasal daily and titrate to 600 mcg based on tolerance. The half-life after intranasal delivery is approximately 30 to 60 minutes, but downstream BDNF elevation persists for 24 hours in animal models [9]. Reported side effects are mild: nasal irritation, transient headache, and mild stimulant-like effects at higher doses.

Selank: Anxiolytic Properties and the IL-6 Connection

Selank (TKPRPGP) is a synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences specifically to extend tuftsin's immunomodulatory and anxiolytic activity into a metabolically stable form [12].

The compound modulates GABA-A receptor sensitivity without direct benzodiazepine-site binding. In a placebo-controlled crossover study (N=62) in patients with generalized anxiety disorder, selank 250 mcg intranasal twice daily for 14 days produced a statistically significant reduction in Hamilton Anxiety Rating Scale scores compared with placebo (mean reduction 7.1 versus 2.4 points, P<0.001) [13]. The study found no withdrawal syndrome on discontinuation, and no sedation measured by psychomotor testing, differentiating selank from benzodiazepines pharmacologically.

The IL-6 angle is clinically interesting. Animal studies show selank downregulates pro-inflammatory IL-6 in hippocampal tissue while simultaneously upregulating mRNA for BDNF and serotonin transporter [14]. Whether this anti-inflammatory effect translates to meaningful benefit in humans with neuroinflammatory conditions is unknown; no human trial has specifically enrolled a neuroinflammation-defined population.

Selank is approved in Russia for anxiety and asthenic conditions. In the U.S. it is not FDA-approved. The typical intranasal dose used in research is 250 to 500 mcg daily. Because it lacks direct GABA-A agonism, physiological dependence is unlikely but cannot be excluded without longer human safety studies.

Dihexa: The Hepatocyte Growth Factor Angle

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small-molecule peptidomimetic derived from angiotensin IV. It was developed at Washington State University by Joseph Harding's laboratory. Unlike the other compounds in this article, dihexa is orally bioavailable, which sets it apart from most peptides that require injection or nasal delivery [15].

Dihexa's primary mechanism is potentiation of hepatocyte growth factor (HGF) binding to its receptor c-Met. HGF/c-Met signaling drives synaptogenesis, specifically the formation of new functional synapses in hippocampal circuits. In a Morris water maze model of cognitive impairment, dihexa reversed scopolamine-induced spatial memory deficits at a dose approximately 1,000-fold lower than its parent compound, angiotensin IV [15]. The same Washington State team reported that subcutaneous dihexa rescued memory deficits in aged rats and in a rodent model of Alzheimer's pathology [16].

No peer-reviewed human clinical trial has been published for dihexa as of this article's review date. This is a meaningful gap. Animal data, even compelling animal data, has not reliably predicted human cognition outcomes in the neurodegeneration field. The c-Met receptor is also expressed on many non-neuronal tissues, including liver and lung epithelium. Long-term c-Met potentiation raises theoretical oncological concerns that no safety study has yet addressed in humans [17].

The clinical framework our medical team applies before considering dihexa: no active malignancy, no personal or first-degree family history of hepatocellular carcinoma, normal liver function panel at baseline, and re-check at 60 days. These criteria are not derived from published guidelines because none exist yet. They represent the conservative standard our team applies until human safety data emerges.

Given the absence of human trial data, the estimated human dose range of 10 to 30 mg orally is extrapolated from animal allometric scaling and is not validated. Physicians at HealthRX treat dihexa as an investigational compound and do not routinely prescribe it outside a structured monitoring arrangement.

Pinealon: Epigenetic Mechanisms and the Aging Brain

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), originally developed and studied by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology [18]. The Khavinson group proposed that short peptides of this class function as "signal peptides" that enter cell nuclei and modulate gene transcription directly, influencing histone acetylation and chromatin accessibility rather than acting through classical surface receptors [18].

Preclinical data for pinealon focuses on retinal neuroprotection and age-related neurodegeneration. In a rat model of retinal ischemia, pinealon 100 mcg/kg subcutaneously daily for 5 days reduced retinal ganglion cell loss by 38% compared with saline control (P<0.05) [19]. A separate study in senescence-accelerated mice showed that pinealon improved performance on open-field exploration tests and reduced markers of oxidative stress in hippocampal tissue at 6 weeks [20].

Human data for pinealon is sparse. Khavinson's group published an open-label series in elderly patients (N=78, mean age 71) with age-associated memory impairment showing improvement on the Mini-Mental State Examination at 3 months after three 10-day peptide courses [21]. Open-label series without a control arm cannot distinguish drug effect from regression to the mean, natural variation, or placebo response.

Pinealon is not FDA-approved and has no approved status in major Western regulatory jurisdictions. It is sometimes sold as a research chemical. The lack of controlled human data is the defining limitation. The epigenetic mechanism hypothesis is biologically plausible, but demonstrating functional changes in human chromatin structure in vivo remains technically and methodologically difficult.

Comparing the Five Compounds: Evidence Tiers

Not all five compounds sit at the same evidentiary level, and conflating them does patients a disservice.

Tier 1: Meaningful human RCT data. Cerebrolysin has the strongest evidence base, with multiple Phase II and Phase III trials totaling more than 2,000 randomized patients across stroke and Alzheimer's indications. Semax has smaller but controlled Russian trials in stroke, with a combined enrollment approaching 600 patients across published studies [10].

Tier 2: Controlled human evidence, limited scale. Selank has at least one placebo-controlled RCT (N=62) with a valid primary endpoint. This is better than most peptides in commercial circulation, but the study was single-site and has not been independently replicated in a Western regulatory context.

Tier 3: Animal or open-label data only. Dihexa has no peer-reviewed human RCT. Pinealon has an open-label series that cannot support efficacy claims.

This tiering matters because clinicians and patients evaluating these compounds need to calibrate expectations appropriately. A Tier 1 compound like cerebrolysin might reasonably be considered in an off-label context with informed consent. A Tier 3 compound like dihexa warrants far greater caution and explicit acknowledgment of uncertainty.

Safety, Drug Interactions, and Regulatory Status

Cerebrolysin is generally well tolerated in published trials. The most common adverse events are injection-site reactions, mild dizziness, and agitation at doses above 30 mL [3]. Serious adverse events in the CASTA trial (N=1,070) were not significantly different between cerebrolysin and placebo groups [4]. Because it is porcine-derived, it is contraindicated in patients with pork protein hypersensitivity, and theoretically in patients with prion-disease risk (though no clinical case of prion transmission from cerebrolysin has been published).

Semax at 600 mcg intranasal has no documented serious adverse events in published trials, but the absence of a large long-term safety dataset is the main caveat [10]. The mild stimulant profile means it could theoretically worsen anxiety or insomnia in susceptible individuals.

Selank's safety profile in the N=62 RCT showed no serious adverse events and no clinically significant changes in liver function, CBC, or metabolic panel at 14 days [13]. The short duration limits conclusions about longer exposure.

Dihexa's safety in humans is simply unknown. The c-Met potentiation concern described above is theoretical but not trivial [17].

Pinealon has no documented human toxicity, but absence of reported harm in a compound with minimal human exposure is not the same as a demonstrated safety profile [21].

Drug interactions. No formal pharmacokinetic interaction studies exist for any of these five compounds with commonly prescribed drugs. Theoretical interactions include additive sedation with benzodiazepines for selank, and possible additive bleeding risk for cerebrolysin co-administered with thrombolytics in stroke settings. Clinicians should apply the standard principle: assume an interaction is possible until proven otherwise, especially in patients on anticoagulants, antiepileptics, or psychiatric medications.

U.S. regulatory status. None of the five compounds is FDA-approved for any indication. Under FDA regulations at 21 CFR Part 503A, compounding pharmacies may prepare certain unapproved drugs for individual patient prescriptions, but all five compounds occupy a grey area. Patients obtaining these compounds from overseas or from non-FDA-regulated internet vendors carry the full quality-control risk [22].

Patient Selection: Who May Benefit and Who Should Avoid These Compounds

The HealthRX medical team applies a structured intake before considering any neurotropic peptide:

1. Confirm that modifiable causes of cognitive decline (hypothyroidism, vitamin B12 deficiency, obstructive sleep apnea, medication side effects) have been evaluated and addressed.
2. Obtain baseline CBC, comprehensive metabolic panel, thyroid panel, vitamin B12, and a validated cognitive screen (MoCA or MMSE).
3. Discuss the evidence tier of the specific compound being considered, as outlined above.
4. Document informed consent specifying the investigational or off-label status, known and unknown risks, and lack of FDA approval.
5. For dihexa specifically, exclude active malignancy and evaluate hepatic function before initiating and at 60 days.
6. For cerebrolysin, confirm no pork protein allergy and verify sterile IV preparation from a licensed compounding pharmacy with certificate of analysis.

Absolute contraindications across the group include active malignancy, pregnancy, known hypersensitivity to the compound or its vehicle, and age <18 years (no pediatric safety data for any of these outside limited Russian studies).

Relative contraindications include severe hepatic or renal impairment, autoimmune disease on active immunosuppression, and concurrent use of CNS-active drugs without specialist co-management.

How Neurotropic Peptides Fit Into a Broader Brain Health Protocol

These compounds do not replace established interventions. Aerobic exercise increases BDNF by approximately 200 to 300% in the hippocampus of rodent models, and a 2022 meta-analysis of 14 human RCTs (N=737) found that 150 minutes per week of moderate aerobic exercise produced statistically significant improvements on the Montreal Cognitive Assessment at 6 months (mean improvement 1.2 points, P<0.001) [23]. Sleep optimization, cardiovascular risk factor control, and dietary quality all have stronger and longer evidence bases than any of the five peptides discussed here.

The reasonable clinical role for neurotropic peptides is as adjunctive options in patients who have already optimized lifestyle factors, have a specific indication aligned with available trial data (acute stroke recovery for cerebrolysin or semax, anxiety with neuroinflammatory features for selank), and have undergone appropriate baseline evaluation.